Benchling Raises $200M Series E To Accelerate Biotech R&D

23 Apr, 2021

Benchling Raises $200M Series E To Accelerate Biotech R&D
Photo by Andrei Ianovskii on Unsplash

– Benchling has raised $200m in Series E funding led by Sequoia Capital Global Equities and joined by Altimeter Capital, Byers Capital and Elad Gil.
– Existing investors participated, including Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital and Lead Edge Capital.
– The company will use the funding to aggressively invest in product development and global expansion to support enterprise customers.
– Since launching in 2012, more than 300,000 scientists and 1,000 R&D organizations around the globe have adopted Benchling’s cloud platform to manage massively complex experimental datasets and optimize R&D processes.

Biotechnology Enterprise Software Life Science North America Software
Crunchbase icon

Content report

The following text will be sent to our editors: